{"id":"tp-21313","type":"article-newspaper","title":"Ascendis Pharma Reports Strong Phase 3 Durability Data for Yorvipath","author":"Token Post","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/21313","datePublished":"2026-06-15T04:26:45.000Z","dateModified":"2026-06-15T04:26:45.000Z","language":"en","abstract":"Ascendis Pharma reported long-term Phase 3 data showing Yorvipath sustained biochemical control and reduced supplement reliance in hypoparathyroidism patients over 3.5 years.","section":"Business","references":[]}